DHR vs NVDA: Which Is the Better Buy?

Side-by-side comparison of Danaher Corporation and NVIDIA Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-04.
Danaher Corporation Β· Healthcare
$174.04
+13.2% upside to fair value
Grade B
VS
NVIDIA Corporation Β· Technology
$182.08
+59.3% upside to fair value
High Conviction Grade A-
QuantHub Verdict
NVDA has more upside to fair value (+59.3%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric DHR NVDA
Current Price $174.04 $182.08
Fair Value Estimate $197.01 $290.00
Upside to Fair Value +13.2% +59.3%
Market Cap $123.2B $4,425.5B
Forward P/E 33.4x β€”
EV / EBITDA 20.3x 31.4x
Price / Sales 5.0x 21.0x
Price / FCF 23.3x 46.9x
Revenue Growth YoY +3.7% +65.5%
Gross Margin 60.7% 71.1%
Operating Margin 21.0% 60.4%
Return on Equity 7.1% 76.3%
Dividend Yield 0% 0.02%
FCF Yield 4.3% 2.13%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
DHR β€” Danaher Corporation
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
NVDA β€” NVIDIA Corporation
NVIDIA is the foundational infrastructure layer of the AI era. Data Center revenue reached $193.7B in FY2026, up 66% YoY, powered by insatiable demand for Blackwell B200 GPUs across hyperscalers and sovereign AI programs. The company generates $96.7B in annual free cash flow with 71% gross margins and 56% net margins, making it the most profitable semiconductor business in history. At P/E 37.7x v…
Accumulation Zones
Metric DHR NVDA
Zone Low $147.76 $218.00
Zone High $167.46 $250.00
In Buy Zone? No Yes
← DHR Research    NVDA Research β†’    All Research